📊 ACB Key Takeaways
Is Aurora Cannabis Inc. (ACB) a Good Investment?
Aurora Cannabis presents a severely compromised fundamental analysis with insufficient financial data available for proper evaluation. The absence of critical financial metrics including revenue, profitability measures, balance sheet details, and cash flow statements indicates either recent delisting activity, data reporting issues, or a company in severe financial distress.
Aurora's fundamentals show a real improvement in business quality at the core medical cannabis segment, with FY2025 net revenue rising to C$343.3 million from C$269.6 million and continuing-operations income turning positive. However, the latest interim results weaken the near-term picture: first-half FY2026 operating cash flow was negative, net losses widened due to impairment charges, and debt was reclassified current after a covenant breach, so the company looks operationally improved but not yet financially de-risked.
Why Buy Aurora Cannabis Inc. Stock? ACB Key Strengths
- Operates in medicinal chemicals and botanical products sector with legitimate regulatory framework
- Nasdaq listed entity indicating historical compliance with exchange standards
- Access to capital markets for potential financing needs
- Higher-margin medical cannabis is driving growth, with first-half FY2026 net revenue up to C$188.4 million from C$164.6 million and medical markets contributing the large majority of adjusted gross profit
- FY2025 showed major profitability progress, including continuing-operations net income of C$15.8 million versus a C$57.1 million loss a year earlier and positive operating income of C$4.9 million
- Balance sheet still has meaningful liquidity and modest net leverage on a book basis, including C$95.7 million cash, C$46.3 million restricted cash, and C$567.1 million equity at September 30, 2025
ACB Stock Risks: Aurora Cannabis Inc. Investment Risks
- Complete absence of revenue and profitability data prevents fundamental analysis
- No balance sheet metrics available to assess financial health or solvency
- No cash flow data available to evaluate operational sustainability
- Zero insider buying activity in past 90 days signals lack of management confidence
- Minimal data freshness suggests potential reporting gaps or corporate status changes
- Cannabis industry regulatory uncertainty and banking restrictions create operational headwinds
- First-half FY2026 cash generation deteriorated, with operating cash flow of negative C$30.3 million from continuing operations
- A Bevo covenant breach caused loans to be classified as current, lifting current borrowings to C$59.8 million and raising refinancing and waiver risk
- Earnings quality remains volatile due to biological asset fair-value accounting, a C$31.9 million goodwill and intangible impairment in Q2 FY2026, and disclosed material weaknesses in internal controls
Key Metrics to Watch
- Current quarterly revenue and gross margin trends
- Operating cash flow and working capital position
- Debt levels and covenant compliance status
- Management insider transactions and stock repurchases
- Regulatory licensing status and cultivation/production capacity
- Operating cash flow and free cash flow trend, especially whether medical-cannabis growth converts into sustained cash generation
- Debt covenant resolution and current loan classification, including whether Bevo secures waivers or amended terms without further balance-sheet stress
Aurora Cannabis Inc. (ACB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ACB Profit Margin, ROE & Profitability Analysis
ACB vs Materials Sector: How Aurora Cannabis Inc. Compares
How Aurora Cannabis Inc. compares to Materials sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aurora Cannabis Inc. Stock Overvalued? ACB Valuation Analysis 2026
Based on fundamental analysis, Aurora Cannabis Inc. has mixed fundamental signals relative to the Materials sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aurora Cannabis Inc. Balance Sheet: ACB Debt, Cash & Liquidity
ACB Revenue Growth, EPS Growth & YoY Performance
ACB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aurora Cannabis Inc. (CIK: 0001683541)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ACB
What is the AI rating for ACB?
Aurora Cannabis Inc. (ACB) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 79% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACB's key strengths?
Claude: Operates in medicinal chemicals and botanical products sector with legitimate regulatory framework. Nasdaq listed entity indicating historical compliance with exchange standards. ChatGPT: Higher-margin medical cannabis is driving growth, with first-half FY2026 net revenue up to C$188.4 million from C$164.6 million and medical markets contributing the large majority of adjusted gross profit. FY2025 showed major profitability progress, including continuing-operations net income of C$15.8 million versus a C$57.1 million loss a year earlier and positive operating income of C$4.9 million.
What are the risks of investing in ACB?
Claude: Complete absence of revenue and profitability data prevents fundamental analysis. No balance sheet metrics available to assess financial health or solvency. ChatGPT: First-half FY2026 cash generation deteriorated, with operating cash flow of negative C$30.3 million from continuing operations. A Bevo covenant breach caused loans to be classified as current, lifting current borrowings to C$59.8 million and raising refinancing and waiver risk.
What is ACB's revenue and growth?
Aurora Cannabis Inc. reported revenue of N/A.
Does ACB pay dividends?
Aurora Cannabis Inc. does not currently pay dividends.
Where can I find ACB SEC filings?
Official SEC filings for Aurora Cannabis Inc. (CIK: 0001683541) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACB's EPS?
Aurora Cannabis Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ACB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Aurora Cannabis Inc. has a SELL rating with 79% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ACB stock overvalued or undervalued?
Valuation metrics for ACB: ROE of N/A (sector avg: 14%), net margin of N/A (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy ACB stock in 2026?
Our dual AI analysis gives Aurora Cannabis Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACB's free cash flow?
Aurora Cannabis Inc.'s operating cash flow is N/A, with capital expenditures of N/A.
How does ACB compare to other Materials stocks?
Vs Materials sector averages: Net margin N/A (avg: 10%), ROE N/A (avg: 14%), current ratio N/A (avg: 1.6).